Скачать или смотреть IBRX Stock Analysis: $11.80 Price Target Potential?

IBRX stock has seen a massive rally in January 2026, gaining over 200% on a wave of positive clinical and regulatory news regarding its cancer therapy, ANKTIVA. But is the momentum sustainable?

This video breaks down the latest breaking news, FDA updates, and analyst insights to help you understand the recent volatility and future potential for ImmunityBio shares. We'll cover everything you need to know about ANKTIVA sales, clinical trial data for glioblastoma, and what the analysts are predicting for the stock price in 2026.

IBRX stock, IBRX stock news, IBRX stock price prediction, IBRX stock analysis, IBRX stock forecast, IBRX stock short interest, IBRX stock buy or sell, IBRX stock forum, IBRX stock price target, ImmunityBio stock news, ImmunityBio ANKTIVA FDA approval, ANKTIVA sales, IBRX clinical trials.

Timestamps:
00:00 - IBRX Stock: Breaking News & Massive January Rally
01:45 - ANKTIVA FDA Update & Regulatory Scrutiny Explained
03:30 - Analyst Price Targets and 2026 Outlook for IBRX

#IBRX #ImmunityBio #IBRXStock #StockMarket #BiotechStocks #Investing #StockAnalysis #BreakingNews #FDAApproval #ANKTIVA